Beta-Hydroxyisovalerate Biosynthesis Using Engineered Microorganisms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing beta hydroxyisovalerate (βHIV) are energy-intensive and result in toxic by-products, and there is a need for environmentally benign, cost-effective, and high-quality production processes using renewable feedstocks.
Innovation Solution
Development of non-natural microorganisms engineered to express or overexpress the βHIV metabolic pathway, utilizing genetically modified microorganisms cultured in the presence of carbon sources like glucose, xylose, arabinose, sucrose, and lactose, with enzymes such as βHIV synthase optimized for substrate specificity and localized in the cytosol, and optionally using dioxygenases modified to preferentially utilize α-ketoisocaproate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemical oxidation methods are used to produce beta hydroxyisovalerate, then production efficiency is achieved, but toxic by-products are generated and environmental harm increases
Solution Approach 1:
The patent replaces chemical oxidation methods with biological fermentation using engineered microorganisms. The mechanical/chemical system of chemical reagents and oxidation reactions is substituted with a biological system where microorganisms metabolically convert substrates into beta hydroxyisovalerate through enzymatic pathways, eliminating toxic by-products while maintaining production efficiency
Solution Approach 2:
The patent changes the fundamental production parameters from chemical to biological conditions. By engineering microorganisms with optimized metabolic pathways and culturing them under controlled fermentation conditions, the process achieves high productivity through biological catalysis rather than chemical oxidation, simultaneously avoiding harmful by-products
2Productivity
If conventional production methods are used, then current production capacity is maintained, but energy consumption is excessive
Solution Approach 1:
The engineered microorganisms perform self-service by autonomously converting substrates into beta hydroxyisovalerate through their metabolic pathways. The biological system uses its own enzymatic machinery to catalyze reactions and produce the target compound, eliminating the need for energy-intensive external chemical processing while maintaining high production capacity
Solution Approach 2:
The patent replaces energy-intensive chemical processing equipment and operations with a biological fermentation system. The mechanical energy required for chemical synthesis is substituted with biological energy conversion through microbial metabolism, achieving comparable or superior productivity with significantly reduced energy consumption
3Ease of manufacture
If non-natural microorganisms are engineered to produce beta hydroxyisovalerate, then production cost is reduced and environmental impact is minimized, but process complexity increases
Solution Approach 1:
The patent segments the complex production process into distinct functional modules: substrate uptake systems, metabolic pathway enzymes, and product secretion mechanisms. By engineering microorganisms with modular genetic constructs and separate functional elements, the complex biological process becomes more manageable and cost-effective while maintaining environmental benefits
Solution Approach 2:
The engineered microorganisms exhibit multi-functionality by simultaneously performing substrate conversion, product synthesis, and self-regulation within a single biological system. This universal platform can process various substrates and produce beta hydroxyisovalerate through integrated metabolic pathways, reducing overall process complexity despite the advanced engineering required
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered microorganisms produce βHIV with yields ranging from 0.1% to 99.5% of theoretical yield, avoiding halogen-containing components and reducing environmental impact, thus providing a cost-effective and efficient production method.
Implementation Method 1
Dioxygenases are enzymes that incorporate diatomic oxygen to form oxo-intermediates
Implementation Method 2
To reduce diatomic oxygen, these enzymes require a source of electrons as well as a cofactor capable of one-electron chemistry
Implementation Method 3
methods of producing beta hydroxyisovalerate by culturing the genetically modified microorganisms in the presence of at least one carbon source
Data Source
AI summary
The biological production of beta-hydroxyisovalerate (βHIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active βHIV metabolic pathway for the production of βHIV. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.